I would say that FRX's future is only depends on its sales on Celexa (citalopram).
It took FRX two years to reach $100 mil sales for its Tiazac. FRX was $22.5 and then it went up to $27.5 when FRX licenced Tiazac. it was still around $20 last year. So FRX investors are far behind the whole market.
I realy think Tiazac has almost reached its limit because another company received FDA approal for the same kind of generic version of Cardizm CD (there will be more and more companies). Aerobid, Monurol, and etc. are not big enough to justify FRX's current price. Pipelines, I don't even want consider them. Otherwise I would buy biotech stocks.
I do agree that FRX is ONE product company if we want growth from our investment. Celexa is our bet!!!